Spiro-3-hetero-azolones for treatment of diabetic complications
申请人:Pfizer Inc.
公开号:US04556670A1
公开(公告)日:1985-12-03
Spiro-oxazolidones, -thiazolidones and -imidazolidones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic complications are also disclosed.